 "Sun Pharma rolls out anti-cancer Gemcitabine InfuSMART in Europe")
As part of its business strategy to build a meaningful and differentiating presence in global oncology therapy market, Sun Pharmaceutical Industries has launched anti-cancer drug Gemcitabine InfuSMART - a technology in which oncology products are developed in a ready-to-administer (RTA) bag - in Europe.
Until now, compounding of oncology products was done at compounding centres or compounded in hospital pharmacies, an extra step before the medicine can be administered to patients. “With the rollout of Gemcitabine InfuSMART, Sun Pharma has become the world's first pharmaceutical company to manufacture and launch a licensed RTA oncology product,” said the company in a press release.
Over the next few months, Sun Pharma plans to launch Gemcitabine InfuSMART across the Netherlands, the UK, Spain, Germany, Italy and France.
The NHS (UK) has been encouraging development of licensed RTA products. It has issued guidelines for hospitals for procuring such medicines. The launch of Gemcitabine InfuSMART offers the company a definite first-mover advantage in Europe for cancer treatment, said Sun Pharma.
Hellen de Kloet, business head - Western Europe & ANZ, Sun Pharma, said, “Sun Pharma's Gemcitabine InfuSMART ready-to-administer infusion products provide the combined advantage of long stable compounded medicine along with safety. Traditionally, such medicines are compounded at hospitals (in-house) or outsourced to compounding pharmacies, making it a time-consuming and potentially hazardous process. Launch of InfuSMART will help us remain a meaningful player in the global oncology therapy market by offering differentiating cancer treatment solutions. We believe there are opportunities for us to expand our portfolio of ready-to-administer products across multiple therapies where time and safety are an important element of treatment.”
Until now, compounding of oncology products was done at compounding centres or compounded in hospital pharmacies, an extra step before the medicine can be administered to patients. “With the rollout of Gemcitabine InfuSMART, Sun Pharma has become the world's first pharmaceutical company to manufacture and launch a licensed RTA oncology product,” said the company in a press release.
Over the next few months, Sun Pharma plans to launch Gemcitabine InfuSMART across the Netherlands, the UK, Spain, Germany, Italy and France.
Also Read
Sun Pharma has received regulatory approval to produce Gemcitabine InfuSMART in eight key SKUs (stock keeping units). “More InfuSMART oncology products are currently in Sun Pharma's pipeline to be rolled out in future,” said the company.
The NHS (UK) has been encouraging development of licensed RTA products. It has issued guidelines for hospitals for procuring such medicines. The launch of Gemcitabine InfuSMART offers the company a definite first-mover advantage in Europe for cancer treatment, said Sun Pharma.
Hellen de Kloet, business head - Western Europe & ANZ, Sun Pharma, said, “Sun Pharma's Gemcitabine InfuSMART ready-to-administer infusion products provide the combined advantage of long stable compounded medicine along with safety. Traditionally, such medicines are compounded at hospitals (in-house) or outsourced to compounding pharmacies, making it a time-consuming and potentially hazardous process. Launch of InfuSMART will help us remain a meaningful player in the global oncology therapy market by offering differentiating cancer treatment solutions. We believe there are opportunities for us to expand our portfolio of ready-to-administer products across multiple therapies where time and safety are an important element of treatment.”